(Hypertension. 1998;32:1011-1015.)
© 1998 American Heart Association, Inc.
Scientific Contributions |
From the Cardiology Division and Institute of Clinical Pharmacology, University Hospitals, Bern and Zürich, and Cardiovascular Research, Institute of Physiology, University Zürich, Switzerland.
Correspondence to Dr Thomas F. Lüscher, University Hospital, CH-8091 Zürich, Switzerland.
AbstractAn imbalance between
nitric oxide (NO) and superoxide is importantly involved in the
pathogenesis of vascular disease. Inflammatory stimuli and risk factors
contribute to these alterations. Calcium antagonists and
angiotensin-converting enzyme inhibitors are
commonly used cardiovascular drugs. To clarify the
effect of felodipine and ramiprilat on the balance of these
free radicals, we stimulated human aortic smooth muscle cells (HASCs)
with cytokines (human interleukin-1ß, tumor necrosis
factor-
, lipopolysaccharide, and/or interferon-
) or high
glucose in the presence and absence of these compounds. Felodipine, but
not ramiprilat, concentration-dependently inhibited
cytokine-induced NO production and NO synthase
(NOS) mRNA induction. The antioxidant N-acetylcysteine
also inhibited cytokine-induced NO production and
induction of inducible NOS mRNA. Moreover, felodipine inhibited
cytokine-induced superoxide production both in the
presence and absence of an NOS inhibitor, suggesting that
it acted as a superoxide scavenger and not as an inhibitor
of inducible NOS induction. High glucose treatment (22 mmol/L for
48 hours) also significantly increased superoxide production in
HASCs, and this increase was inhibited in a concentration-dependent
manner by felodipine but not by ramiprilat. These results
suggest that felodipine may exert vascular protective effects by
suppressing free radical generation in human smooth muscle cells during
activation of inflammatory mechanisms and diabetic conditions.
Key Words: nitric oxide free radicals superoxides cytokines glucose
This article has been cited by other articles:
![]() |
J. D. Dietz, S. Du, C. W. Bolten, M. A. Payne, C. Xia, J. R. Blinn, J. W. Funder, and X. Hu A Number of Marketed Dihydropyridine Calcium Channel Blockers Have Mineralocorticoid Receptor Antagonist Activity Hypertension, March 1, 2008; 51(3): 742 - 748. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. Gerzanich, S. Ivanova, M. S. van der Heijden, H. Zhou, and J. M. Simard Trans-Cellular Proliferating Cell Nuclear Antigen Gene Activation in Cerebral Vascular Smooth Muscle by Endothelial Oxidative Injury In Vivo Arterioscler Thromb Vasc Biol, November 1, 2003; 23(11): 2048 - 2054. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Hishikawa, B. S. Oemar, F. C. Tanner, T. Nakaki, T. Fujii, and T. F. Luscher Overexpression of Connective Tissue Growth Factor Gene Induces Apoptosis in Human Aortic Smooth Muscle Cells Circulation, November 16, 1999; 100(20): 2108 - 2112. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. E. Toblli, L. Ferder, M. Angerosa, and F. Inserra Effects of Amlodipine on Tubulointerstitial Lesions in Normotensive Hyperoxaluric Rats Hypertension, October 1, 1999; 34(4): 854 - 858. [Abstract] [Full Text] [PDF] |
||||
|
Hypertension Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 1998 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |